Prevention and suppression of Helicobacter felis infection in mice using colostral preparation with specific antibodies

Helicobacter

Volumn 8, Issue 3, 2003, Pages 192-201

  Marnila, Pertti ^a   Rokka, Susanna ^a   Rehnberg Laiho, Leena ^d   Kärkkäinen, Päivi ^c   Kosunen, Timo U ^d   Rautelin, Hilpi ^b   Hänninen, Marja Liisa ^c   Syväoja, Eeva Liisa ^a   Korhonen, Hannu ^a  

^a FINNISH FOREST RESEARCH INSTITUTE   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c VALIO LTD   (Finland)

^d NONE

Author keywords

Antibody; Helicobacter; Immune colostrum; Passive immunization

Indexed keywords

AMOXICILLIN; ANTIBODY; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COLONIZATION; BACTERICIDAL ACTIVITY; COLOSTRUM; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG ISOLATION; DRUG SYNTHESIS; FEMALE; HELICOBACTER FELIS; HELICOBACTER INFECTION; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOTHERAPY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; STOMACH ANTRUM; TREATMENT OUTCOME;

AMOXICILLIN; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; CATTLE; COLONY COUNT, MICROBIAL; COLOSTRUM; COMBINED MODALITY THERAPY; FEMALE; HELICOBACTER INFECTIONS; IMMUNIZATION, PASSIVE; MICE; PENICILLINS;

ANIMALIA; BACTERIA (MICROORGANISMS); FELIS; HELICOBACTER; HELICOBACTER FELIS; HELICOBACTER PYLORI;

EID: 0037506892     PISSN: 10834389     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-5378.2003.00144.x     Document Type: Article

References (58)

1. Larson BL. Immunoglobulins of the mammary secretions. In: Fox PF, ed. Advanced Dairy Chemistry 1: Proteins. London, UK: Elsevier Science Publishers 1992, 231-54.
2. Butler JE. Passive immunity and immunoglobulin diversity. In: Proceedings of the IDF Seminar. Indigenous Antimicrobial Agents of Milk - Recent Developments. Uppsala Sweden, 31 August & 1 September 1993. Brussels, Belgium: International Dairy Federation 1994, 14-50.
3. Korhonen H, Marnila P, Gill H. Milk immunoglobulins and complement factors: a review. Br J Nutr 2000;84:S75-S80.
4. Levieux D, Ollier A. Bovine immunoglobulin G, β-lactoglobulin, α-lactalbumin and serum albumin in colostrum and milk during the early post partum period. J Dairy Res 1999;66:421-30.
5. Brock JH, Ortega F, Piñeiro A. Bactericidal and haemolytic activity of complement in bovine colostrum and serum: effect of proteolytic enzymes and ethylene glycol tetraacetic acid (EGTA). Ann Immunol 1975;126C:439-51.
6. Pakkanen R, Aalto J. Growth factors and anti-microbial factors of bovine colostrums: a review. Int Dairy J 1997;7:285-97.
7. Playford RJ, MacDonald CE, Johnson WS. Colostrum and milk-derived peptide growth factors for the treatment of gastrointestinal disorders: a review. Am J Clin Nutr 2000;72:5-14.
8. Tacket CO, Losonsky G, Link H, et al. Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med 1988;318:1240-3.
9. Freedman DJ, Tacket CO, Delehanty A, Maneval DR, Nataro J, Crabb JH. Milk immunoglobulin with specific activity against purified colonization factor antigens can protect against oral challenge with enterotoxigenic Escherichia coli. J Infect Dis 1998;177:662-7.
10. Tacket CO, Binion SB, Bostwick E, Losonsky G, Roy MJ, Edelman R. Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge. Am J Trop Med Hyg 1992;47:276-83.
11. Davidson GP, Daniels E, Nunan H, et al. Passive immunisation of children with bovine colostrum containing antibodies to human rotavirus. Lancet 1989;2:709-12.
12. Davidson GP, Tam J, Kirubakaran C. Passive protection against symptomatic hospital acquired rotavirus infection in India and Hong Kong. J Pediatr Gastroenterol Nutr 1994;19:351.
13. Ebina T, Sato A, Umezu K, et al. Prevention of rotavirus infection by oral administration of colostrum containing antihumanrotavirus antibody. Med Microbiol Immunol 1985;174: 177-85.
14. Loimaranta V, Nuutila J, Marnila P, Tenovuo J, Korhonen H, Lilius E. Colostral proteins from cows immunised with Streptococcus mutans/S. sobrinus support the phagocytosis and killing of mutans streptococci by human leukocytes. J Med Microbiol 1999;48:1-10.
15. Davidson GP. Passive protection against diarrhoeal disease. J Pediatr Gastroenterol Nutr 1996; 23:207-12.
16. Weiner C, Pan Q, Hurtig M, Boren T, Bostwick E, Hammarström L. Passive immunity against human pathogens using bovine antibodies. Clin Exp Immunol 1999;116:193-205.
17. Zeitlin L, Cone RA, Moench TR, Whaley KJ. Preventing infectious diseases with passive immunization. Microbes Infections 2000;2:701-8.
18. Korhonen H, Marnila P, Gill H. Bovine milk antibodies for health: a review. Br J Nutr 2000; 84:S135-46.
19. Lilius E-M, Marnila P. The role of colostral antibodies in prevention of microbial infections. Current Opinion Infectious Dis 2001;14:295-300.
20. Peek RM, Blaser MJ. Pathophysiology of Helicobacter pylori-induced gastritis and peptic ulcer disease. Am J Med 1997;102:200-7.
21. Graham DY. Helicobacter pylori infection is the primary cause of gastric cancer. J Gastroenterol 2000;35:90-7.
22. Sjöström JE, Larsson H. Factors affecting growth and antibiotic susceptibility of Helicobacter pylori: effect of pH and urea on the survival of a wildtype strain and a urease-deficient mutant. J Med Microbiol 1996;44:425-33.
23. Lam SK. Differences in peptic ulcer between East and West. Baillieres Best Pract Res Clin Gastroenterol 2000;14:41-52.
24. Moss S, Calam J. Helicobacter pylori and peptic ulcers: the present position. Gut 1992;33:289-92.
25. Graham DY. Treatment of peptic ulcers caused by Helicobacter pylori. N Engl J Med 1993;328:349-50.
26. Glupczynski Y, Labbe M, Burette A, Delmee M, Avesani V, Bruck C. Treatment failure of ofloxacin in Campylobacter pylori infection. Lancet 1987; 1:1096.
27. Goodwin CS, Marshall BJ, Blincow ED, Wilson DH, Blackbourn S, Phillips M. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of bismuth subcitrate. J Clin Pathol 1988;41:207-10.
28. Becx MCJM, Janssen AJHM, Clasener HAL, De Koning RW. Metronidazole-resistant Helicobacter pylori. Lancet 1990;335:539-60.
29. Korhonen H, Syväoja E-L, Ahola-Luttila H, et al. Bactericidal effect of bovine normal and immune serum, colostrum and milk against Helicobacter pylori. J Appl Bacteriol 1995;78:655-62.
30. Tarpila S, Korhonen H, Salminen S. Immune colostrum in the treatment of Helicobacter pylori gastritis. 24th International Dairy Congress. Melbourne, Australia, September 18-22, 1995.
31. Oona M, Rägo T, Maaroos H, et al. Helicobacter pylori in children with abdominal complaints: Has immune bovine colostrum some influence on gastritis? Alpe Adr Microbiol J 1997;6:49-57.
32. Casswall TH, Sarker SA, Albert MJ, et al. Treatment of Helicobacter pylori infection in infants in rural Bangladesh with oral immunoglobulins from hyperimmune bovine colostrum. Aliment Pharmacol Ther 1998;12:563-8.
33. Opekun AR, El-Zaimaity HM, Osato MS, et al. Novel therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 1999;13:35-42.
34. Lee A, Fox JG, Otto G, Murphy J. A small animal model of human Helicobacter pylori active chronic gastritis. Gastroenterology 1990;99:1315-23.
35. Dick-Hegedus E, Lee A. Use of a mouse model to examine anti - Helicobacter pylori agents. Scand J Gastroenterol 1991;26:909-15.
36. Ferrero RL, Avé P, Radcliff FJ, Labigne A, Huerre MR. Outbred mice with long-term Helicobacter felis infection develop both gastric lymphoid tissue and glandular hyperplastic lesions. J Pathol 2000;191:333-40.
37. Höök-Nikanne J, Aho P, Kärkkäinen P, Kosunen TU, Salaspuro M. The Helicobacter felis mouse model in assessing anti-Helicobacter therapies and gastric mucosal prostaglandin E2 levels. Scand J Gastroenterol 1996;31:334-8.
38. Nedrud JG. Animal models for gastric Helicobacter immunology and vaccine studies. FEMS Immunol Med Microbiol 1999;24:243-9.
39. Loimaranta V, Tenovuo J, Virtanen S, et al. Generation of bovine immune colostrums against Streptococcus mutans and Streptococcus sobrinus and its effect on glucose uptake and extracellular polysaccharide formation by mutans streptococci. Vaccine 1997;15:1261-8.
40. International Dairy Federation (IDF) Provisional Standard 20 A. Determination of nitrogen content (Kjeldahl method) and calculation of crude protein content. Brussels, Belgium: International Dairy Federation, 1986.
41. Syväoja E-L, Korhonen H. Determination of colostral immunoglobulins by gel filtration chromatography. In: Indigenous Antimicrobial Agents of Milk - Recent Developments. International Dairy Federation Special Issue no. 9404 1994, 216-9.
42. Rautelin HI, Kosunen T. Campylobacter etiology in human gastroenteritis demonstrated by antibodies to acid extract antigen. J Clin Microbiol 1987;26:1944-51.
43. Sakagami T, Dixon M, O'Rourke J, et al. Atrophic gastric changes in both Helicobacter felis and Helicobacter pylori infected mice are host dependent and separate from antral gastritis. Gut 1996;39:639-48.
44. Price AB. The Sydney System: histological division. J Gastroenterol Hepatol 1991;6:209-22.
45. Czinn SJ, Cai A, Nedrud JG. Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization. Vaccine 1993;11:637-42.
46. Thomas JE, Austin S, Dale A, et al. Protection by human milk IgA against Helicobacter pylori infection in infancy. The Lancet 1993;342:121.
47. Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev 2000; 22:283-97.
48. Petschow BW, Talbott RD. Reduction in virus-neutralizing activity of a bovine colostrum immunoglobulin concentrate by gastric acid and digestive enzymes. J Pediatr Gastroenterol Nutr 1994;19:228-35.
49. Roos N, Mahe S, Benamouzig R, Sick H, Rautureau J, Tome D. 15N-labeled immuno-globulins from bovine colostrum are partially resistant to digestion in human intestine. J Nutr 1995;125:1238-44.
50. Warny M, Fatimi A, Bostwick EF, et al. Bovine immunoglobulin concentrate - Clostridium difficile retains C. difficile toxin neutralising activity after passage through the human stomach and small intestine. Gut 1999;44:212-7.
51. Fishelson Z, Horstmann RD, Müieller-Eberhard HJ. Regulation of the alternative pathway of complement by pH. J Immunol 1987;138:3392-5.
52. Meining A, Wick M, Miehlke S, et al. The presence of immunoglobulins in the gastric juice of patients infected with Helicobacter pylori is related to a reduced secretion of acid. Helicobacter 2002;7:67-70.
53. Early EM, Hardy H, Forde T, Kane M. Bactericidal effect of a whey protein concentrate with anti-Helicobacter pylori activity. J Appl Microbiol 2001;90:741-8.
54. Dial EJ, Hall LR, Serna H, Romero JJ, Fox JG, Lichtenberger LM. Antibiotic properties of bovine lactoferrin on Helicobacter pylori. Dig Dis Sci 1998;43:2750-6.
55. Wada T, Aiba Y, Shimizu K, Takagi A, Miwa T, Koga Y. The therapeutic effect of bovine lactoferrin in the host infected with Helicobacter pylori. Scand J Gastroenterol 1999;34:238-43.
56. Wang X, Sjunnesson H, Sturegard E, Wadstrom T, Willen R, Aleljung P. Dietary factors influence the recovery rates of Helicobacter pylori in a BALB/cA mouse model. Zentralbl Bakteriol 1998;288:195-205.
57. Tanigawa T, Kawamori T, Iimuro M, et al. Marked enhancement by fish meal of Helicobacter pylori-induced gastritis in Mongolian gerbils. Jpn J Cancer Res 2000;91:769-73.
58. Toyonaga A, Okamatsu H, Sasaki K, et al. Epidemiological study on food intake and Helicobacter pylori infection. Kurume Med J 2000;47:25-30.